Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
The objective of this study is to evaluate the efficacy and the tolerability of oral parnaparin sodium (210mg), administered in extended-release tablets identified as CB-01-05-MMX™.
Epistemonikos ID: d4524ab746b80f417ea50fabeccaa8fe245231b9
First added on: Mar 23, 2022